Media stories about Spectrum Pharmaceuticals (NASDAQ:SPPI) have trended somewhat positive recently, according to Accern. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Spectrum Pharmaceuticals earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 47.4137498072667 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:
- Spectrum Pharma’s poziotinib continues to show positive action in mid-stage lung cancer study; shares up 7% premarket (seekingalpha.com)
- Spectrum Pharmaceuticals Announces Release of Poziotinib Abstract as Part of the IASLC 19th World Conference on Lung Cancer (businesswire.com)
- Zacks: Analysts Anticipate Spectrum Pharmaceuticals, Inc. (SPPI) Will Post Quarterly Sales of $25.65 Million (americanbankingnews.com)
- Spectrum Pharmaceuticals: Buy Or Sell Before September Data? (seekingalpha.com)
- Spectrum Pharmaceuticals, Inc. (SPPI) Expected to Post Earnings of -$0.20 Per Share (americanbankingnews.com)
NASDAQ:SPPI opened at $21.05 on Thursday. The company has a market cap of $2.28 billion, a P/E ratio of -19.67 and a beta of 1.85. Spectrum Pharmaceuticals has a fifty-two week low of $9.03 and a fifty-two week high of $25.29.
Spectrum Pharmaceuticals (NASDAQ:SPPI) last posted its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.21) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.02. The firm had revenue of $24.17 million during the quarter, compared to analysts’ expectations of $27.58 million. Spectrum Pharmaceuticals had a negative net margin of 41.24% and a negative return on equity of 27.71%. The firm’s quarterly revenue was down 29.5% on a year-over-year basis. During the same quarter last year, the company posted ($0.11) EPS. analysts expect that Spectrum Pharmaceuticals will post -0.94 earnings per share for the current fiscal year.
A number of equities analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $33.00 price objective on shares of Spectrum Pharmaceuticals in a research report on Friday, June 29th. Zacks Investment Research cut shares of Spectrum Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, May 14th. BidaskClub raised shares of Spectrum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, May 11th. B. Riley increased their price objective on shares of Spectrum Pharmaceuticals from $26.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, August 31st. Finally, TheStreet raised shares of Spectrum Pharmaceuticals from a “d+” rating to a “c” rating in a research report on Monday, August 20th. Two analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. Spectrum Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $30.40.
Spectrum Pharmaceuticals Company Profile
Spectrum Pharmaceuticals, Inc develops and commercializes oncology and hematology drug products. The company markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for peripheral T-cell lymphoma (PTCL); ZEVALIN injection for patients with B-cell non-Hodgkin's lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients.
See Also: Index Funds
Receive News & Ratings for Spectrum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.